$GBT - Older Article Quotes Back in November, when Breidenbach initiated coverage of Global Blood, he wrote in a note: "With promising early clinical data in hand, we believe Global Blood could be an attractive takeout target for any large biopharmaceutical company looking to expand its hematology portfolio." In an interview on Wednesday, Breidenbach noted that among the other pharmaceutical companies that are small-molecule-focused with an ongoing interest in hematological drugs is Pfizer (PFE - Get Report) . Pfizer, he said, "already has a small molecule program specifically in sickle cell disease (rivipansel) but that's for treatment of vaso-occlusive crises in an acute setting. GBT-440 would be used more as preventative medicine and could address all the other clinical consequences of sickle cell disease, including VOCs."
  • 3
  • 2